Jinxin Fertility Posts Solid Early-2026 Growth on China and Overseas IVF Demand

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Jinxin Fertility Group Ltd. ( (HK:1951) ) just unveiled an announcement. Jinxin Fertility Group Limited reported that for the four months ended April 30, 2026, new patient visits for infertility rose 7.5% year on year to 16,525 and oocyte pick-up cycles increased 5.2% to 9,010, underscoring continued demand for its assisted reproduction services. Management said pricing remained stable and revenue growth steady, indicating resilient operations across its network. Growth was strongest in the Greater Bay Area and overseas markets, where new capacity in Shenzhen, clinic upgrades in Hong Kong and policy support in California drove double-digit increases and record overseas procedure volumes. The Chengdu region saw slight declines linked to longer preconception genetic screening timelines under China’s latest fertility policies, but third-generation IVF cycles surged 16.8%, suggesting a shift toward more advanced, higher-value treatments. Kunming and Wuhan maintained solid momentum with a 15.5% rise in oocyte pick-up cycles, reflecting balanced regional expansion for the group. Overall, the operating data highlight Jinxin Fertility’s ability to capture policy-driven and international growth opportunities while navigating localized regulatory impacts, supporting its competitive position in China’s and overseas fertility services markets. The most recent analyst rating on (HK:1951) stock is a Buy with a HK$3.80 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page. More about Jinxin Fertility Group Ltd. Jinxin Fertility Group Limited is a Cayman Islands–incorporated provider of assisted reproductive services, including in vitro fertilization and related infertility treatments. The group operates reproductive medicine hospitals and clinics across mainland China’s Chengdu, Greater Bay Area, Kunming and Wuhan regions, as well as overseas, with a focus on integrated, end-to-end fertility and obstetrics care pathways. Average Trading Volume: 18,827,187 Technical Sentiment Signal: Sell Current Market Cap: HK$6.54B Learn more about 1951 stock on TipRanks’ Stock Analysis page.